Descrizione del progetto
Comprensione dei tumori maligni correlati alla terapia
I sopravvissuti a un cancro infantile spesso presentano malignità correlate alla terapia a seguito dell’esposizione alla chemioterapia o radioterapia. Tuttavia, i dettagli meccanicistici di come emergono queste neoplasie secondarie sono poco conosciuti. Lo scopo del progetto SecondCANCERinKIDS, finanziato dall’UE, è quello di studiare come le mutazioni si accumulano nelle cellule staminali ematopoietiche e danno quindi origine a neoplasie mieloidi correlate alla terapia (t-MN). A tale scopo, gli scienziati studieranno i lignaggi delle cellule ematopoietiche nei bambini prima e dopo aver ricevuto una chemioterapia per determinare se i cloni maligni preesistevano o venivano generati come conseguenza del trattamento. I risultati dimostreranno come la chemioterapia influenza la composizione del sangue e forniranno nuove intuizioni sull’origine del cancro.
Obiettivo
Therapy-related malignancies are a major cause of long-term mortality among childhood cancer survivors. However, it is unclear how exposure to chemo- and/or radiotherapy early in life induces carcinogenesis. My aim is to determine the mechanisms and rate-limiting steps underlying the genesis of second malignancies in childhood cancer survivors. For this, we will focus on studying the etiology of therapy-related myeloid malignancies (t-MNs). I have pioneered methods to characterize mutation accumulation in single stem cells and study clonal lineages in the human hematopoietic system. My lab is embedded in Europe’s largest childhood cancer center, providing the opportunity to apply our techniques to unique patient material. In Objective 1, we will dissect the life history of t-MN and study its cellular origin. Our key question is: Was the original t-MN clone already present before chemotherapy exposure, or generated as a consequence thereof? We will address this by tracking back clonal lineages in the hematopoietic tissue of patients using the mutations present in their second cancers. In Objective 2, we will study the mutational consequences of chemotherapy in normal hematopoietic cells of children before and after they received treatment. Our key question is: Is enhanced mutagenesis rate limiting for t-MN development? To address this, we will perform in-depth mutational analyses and in vitro validations. In Objective 3, we will determine phenotypic effects of chemotherapy on population dynamics of blood. Our key question is: how does chemotherapy affect selection dynamics and clonal composition of blood? To address this, we will integrate clonal histories and lineage contributions using somatically acquired mutations. Our unique methodology and anticipated novel insights will not contribute to improved survival of children with cancer, but also to increased fundamental knowledge on the origin of cancer.
Campo scientifico
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
Programma(i)
Argomento(i)
Meccanismo di finanziamento
ERC-COG - Consolidator GrantIstituzione ospitante
3584CS Utrecht
Paesi Bassi